A clinical trial testing the oral therapy tebapivat for sickle cell disease is fully enrolled, with early results expected later this year.

In a defining breakthrough for the global fight against thalassaemia, the US Food and Drug Administration (FDA) has approved ...

Agios Pharmaceuticals has reported full-year 2025 results, with revenue rising to US$54.03 million from US$36.50 million a year earlier, while swinging from net income of US$673.73 million to a net ...

Agios Pharmaceuticals AGIO reported a loss of $1.85 per share in the fourth quarter of 2025, narrower than the Zacks ...

Study reveals that reversible chemical modifications can inhibit pyruvate kinase and affect its variants differently, ...

Researchers from the University of Seville have participated in research to identify the molecular details of the regulation of an enzyme essential for sugar metabolism and closely linked to cell ...